A study by Korkaya et al. attempted to inhibit the IL-6/STAT-3/NF-κB loop by functional blocking of IL-6 through an anti-IL-6 receptor antibody and found a decreased chemoresistance of HER2 breast cancer cells against trastuzumab [100]. This evidence concerns the gene IL6 and breast carcinoma.